SCM Pharma has once again passed its biennial inspection from the Medicines and Health Care Products Regulatory Agency (MHRA).

The successful audit means the UK-based company will continue supplying products for clinical trials and commercial pharmaceutical projects from its state-of-the-art cGMP-compliant manufacturing, development and packaging facility.

The MHRA audit is a requirement of the European Union Clinical Trials Directive (2001/20/EC) and it means SCM can continue working on its clients’ Investigational Medicinal Products (IMPs) for pre-clinical, Phase 1/II/III and commercial stages.

Jennifer Watson, quality manager at SCM Pharma, said: “We are delighted to have once again been approved by the MHRA. The news is testament to the ongoing commitment of all staff on site to work to standards well beyond the industry norm.”